Familial dysalbuminemic hyperthyroxinemia may result in altered warfarin pharmacokinetics

Chemico-Biological Interactions

Volumn 124, Issue 3, 2000, Pages 161-172

  Petersen, Charles E ^a   Ha, Chung Eun ^a   Harohalli, Krishna ^a   Park, David S ^a   Bhagavan, Nadhipuram V ^a  

^a UNIVERSITY OF HAWAII   (United States)

Author keywords

Familial dysalbuminemic hyperthyroxinemia; Human serum albumin; Pharmacokinetics; Warfarin

Indexed keywords

HUMAN SERUM ALBUMIN; RECOMBINANT PROTEIN; THYROXINE; WARFARIN; ARGININE; HISTIDINE; SERUM ALBUMIN;

AMINO ACID SUBSTITUTION; ARTICLE; DRUG PROTEIN BINDING; EQUILIBRIUM DIALYSIS; FLUORESCENCE; GENOTYPE; HUMAN; HYPERTHYROXINEMIA; IN VITRO STUDY; ISOTOPE LABELING; BLOOD; DIALYSIS; GENE EXPRESSION REGULATION; GENETICS; KINETICS; METABOLISM; MUTATION; PROTEIN BINDING; SPECTROFLUOROMETRY;

AMINO ACID SUBSTITUTION; ARGININE; DIALYSIS; HISTIDINE; HUMANS; HYPERTHYROXINEMIA; KINETICS; MUTAGENESIS, INSERTIONAL; MUTATION; PROTEIN BINDING; SERUM ALBUMIN; SPECTROMETRY, FLUORESCENCE; WARFARIN;

EID: 0033625049     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(99)00143-X     Document Type: Article

References (26)

1. Petersen C.E., Scottolini A.G., Cody L.R., Mande M., Riemer N., Bhagavan N.V. A point mutation in the human serum albumin gene results in familial dysalbuminemic hyperthyroxinemia. J. Med. Genet. 31:1994;355-359.
2. Sunthornthepvarakul T., Angekeow P., Weis R.E., Hayashi Y., Refetoff S. An identical missense mutation in the albumin gene results in familial dysalbuminemic hyperthyroxinemia in 8 unrelated families. Biochem. Biophys. Res. Commun. 202:1994;781-787.
3. Wada N., Chiba H., Shimizu C., Kijima H., Kubo M., Koike T. A novel missense mutation in codon 218 of the albumin gene in a distinct phenotype of the familial dysalbuminemic hyperthyroxinemia in a Japanese kindred. J. Clin. Endocrinol. Metab. 82:1997;246-250.
4. He X.M., Carter D.C. Atomic structure and chemistry of human serum albumin. Nature. 358:1992;208-215.
5. Sudlow G., Birkett D.J., Wade D.N. Spectroscopic techniques in the study of protein binding: A fluorescence technique for the evaluation of albumin binding and displacement of warfarin and warfarin-alchohol. Clin. Exp. Pharmacol. Physiol. 2:1975;129-140.
6. Sudlow G., Birkett D.J., Wade D.N. Further characterization of specific drug binding sites on human serum albumin. Mol. Pharmacol. 12:1976;1052-1061.
7. Petersen C.E., Ha C.-E., Harohalli K., Park D.S., Feix J., Isozaki O., Bhagavan N.V. Investigations of two unique genotypes that result in familial dysalbuminemic hyperthyroxinemia. Clin. Chem. 45(8):1999;1248-1255.
8. Scottolini A.G., Bhagavan N.V., Oshiro T., Powers L. Familial dysalbuminemic hyperthyroxinemia: a study of four probands and a kindred of three. Clin. Chem. 30:1984;1179-1181.
9. Lee W.N.P., Golden M.P., Van Herlem A.J., Lippe B.M., Kaplan S.A. Inherited abnormal thyroid hormone-binding protein causing selective increase of total serum thyroxine. J. Clin. Endocrinol. Metab. 49:1979;292-299.
10. Stockight J.R., Topliss D.J., Barlow J.W., White E.L., Hurley D.M., Taft P. Familial euthyroid thyroxine excess: an appropriate response to abnormal thyroxine binding associated with albumin. J. Clin. Endocrinol. Metab. 53:1981;353-359.
11. Docter R., Bos G., Krenning E.P., Fekkes D., Visser T.J., Hennemann G. Inherited thyroxine excess: a serum abnormality due to an increased affinity for modified albumin. Clin. Endocrinol. 15:1981;363-371.
12. Borst G.D., Premachandra B.N., Burman K.D., Osborne R.C., Georges L.P., Johnsonbaugh R.E. Euthyroid familial hyperthyroxinemia due to abnormal thyroid hormone binding protein. Am. J. Med. 73:1982;283-289.
13. Petersen C.E., Ha C.-E., Harohalli K., Park D.S., Bhagavan N.V. Mutagenesis studies of thyroxine binding to human serum albumin define an important structural characteristic of subdomain 2A. Biochemistry. 36:1997;7012-7017.
14. Petersen C.E., Ha C.-E., Jameson D.M., Nadhipuram N.V. Mutations in a specific human serum albumin thyroxine binding site define the structural basis of familial dysalbuminemic hyperthyroxinemia. J. Biol. Chem. 271:1996;19110-19117.
15. Barlow J.W., Crissmann J.M., White E.L., Funder J.W., Stockigt J.R. Familial euthyroid thyroxine excess: characterization of abnormal intermediate affinity thyroxine binding to albumin. J. Clin. Endocrinol. Metab. 55:1982;244-250.
16. Petersen C.E., Ha C.-E., Mandel M., Bhagavan N.V. Expression of a human serum albumin variant with high affinity for thyroxine. Biochem. Biophys. Res. Commun. 214:1995;1121-1129.
17. Arevalo G. Prevalence of familial dysalbuminemic hyperthyroxinemia in serum samples received for thyroid testing. Clin. Chem. 37:1991;1430-1431.
18. Yacobi A., Udall J.A., Levy G. Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect. Clin. Pharmacol. Ther. 19:1976;552-558.
19. Piroli R.J., Passananti G.T., Shively C.A., Vesell E.S. Antipyrine and warfarin disposition in a patient with idiopathic hypoalbuminemia. Clin. Pharmacol. Ther. 30:1981;810-816.
20. Minghetti P.P., Ruffner D.E., Kuang W.J., Dennison O.E., Hawkins J.W., Beattie W.G., Dugaiczyk A. Molecular structure of the human albumin gene is revealed by nucleotide sequence within q11-22 of chromosome 4. J. Biol. Chem. 261:1986;6747-6757.
21. Glatz J.F.C., Veerkamp J.H. Removal of fatty acids from serum albumin by Lipidex 1000 chromatography. J. Biophys. Methods. 8:1983;57-61.
22. Sadako K.-M., Horie T., Awazu S. Influence of the N-B transition of human serum albumin on the structure of the warfarin binding site. Biochim. Biophys. Acta. 915:1987;277-283.
23. Brown N.A., Jahnchen E., Muller W.E., Wollert U. Optical studies on the mechanism of the interaction of the enantiomers of the anticoagulant drugs phenprocoumon and warfarin with human serum albumin. Mol. Pharmacol. 13:1977;70-79.
24. Kragh-Hansen U., Brennan S.O., Galliano M., Sugita O. Binding of warfarin, salicyclate, and diazepam to genetic variants of human serum albumin with known mutations. Mol. Pharmacol. 37:1989;238-242.
25. Madsen B.W., Ellis G.M. Cooperative interaction of warfarin and phenylbutazone with human serum albumin. Biochem. Pharmacol. 30:1981;1169-1173.
26. Hulse M.L. Warfarin resistance: diagnosis and therapeutic alternatives. Pharmacotherapy. 16:1996;1009-1017.